IDARUBICIN HYDROCHLORIDE
Post-LOEANDAINTRAVENOUSSOLUTION
Approved
Mar 2011
Lifecycle
Post-LOE
Competitive Pressure
30/100
Data completeness
2/8 — Basic
IDARUBICIN HYDROCHLORIDE by Novartis is dna, inhibiting nucleic acid synthesis, inhibiting topoisomerase ii activity, and producing dna-damaging free radicals. First approved in 2011.
Drug data last refreshed 20h ago
Mechanism of Action
DNA, inhibiting nucleic acid synthesis, inhibiting topoisomerase II activity, and producing DNA-damaging free radicals.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Company
Novartis
BASEL, Switzerland
Worked on IDARUBICIN HYDROCHLORIDE at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.